Literature DB >> 15913487

Clinical trials report. Race at ASCOT coming to a halt.

Franz H Messerli1.   

Abstract

Year:  2005        PMID： 15913487     DOI： 10.1007/s11906-005-0003-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  5 in total

1.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

2.  Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.

Authors:  P S Sever; B Dahlöf; N R Poulter; H Wedel; G Beevers; M Caulfield; R Collins; S E Kjeldsen; G T McInnes; J Mehlsen; M Nieminen; E O'Brien; J Ostergren
Journal:  J Hypertens       Date:  2001-06       Impact factor: 4.844

3.  Atenolol in hypertension: is it a wise choice?

Authors:  Bo Carlberg; Ola Samuelsson; Lars Hjalmar Lindholm
Journal:  Lancet       Date:  2004 Nov 6-12       Impact factor: 79.321

Review 4.  beta-Blockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension.

Authors:  Franz H Messerli; D Gareth Beevers; Stanley S Franklin; Thomas G Pickering
Journal:  Am J Hypertens       Date:  2003-10       Impact factor: 2.689

5.  Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review.

Authors:  F H Messerli; E Grossman; U Goldbourt
Journal:  JAMA       Date:  1998-06-17       Impact factor: 56.272
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.